[Artificial urinary sphincter in patients with urinary incontinence after High Intensity Focused ultrasound]. / Sphincter urinaire artificiel chez les patients présentant une incontinence urinaire après High Intensivity Focused Ultrasound Therapy.

INTRODUCTION: Urinary incontinence after High Intensity Focused ultrasound (HIFU) is a poorly documented issue. To our knowledge, no study has evaluated the outcomes of artificial urinary sphincter (AUS) after HIFU. The aim of this study was to evaluate the functional outcomes of AUS for post-HIFU urinary incontinence. METHODS: The charts of all male patients who underwent an AUS implantation between 2004 and 2020 in 13 centers were reviewed retrospectively. Only men with a history of HIFU were included. The primary endpoint was social continence at 3 months defined as wearing 0 to 1 pad per day. RESULTS: Out of 1318 procedures, nine men were implanted with an AUS after HIFU including four men with an history of pelvic irradiation: 3 pelvic radiation therapy and 1 prostatic brachytherapy. The patients were divided into two groups, 5 in the HIFU group without a history of pelvic irradiation, 4 patients in the HIRX group with a history of pelvic irradiation. The median age was 74 years (IQR 71-76). There was no perioperative complication. The median follow-up was 47.5 (IQR 25-85.5) months. Social continence at 3 months was 75% in the total cohort: 80% in the HIFU group and 67% in the HIRX group. CONCLUSION: AUS implantation may provide satisfactory long-term functional outcomes in the treatment of stress urinary incontinence resulting from HIFU. Larger series are needed to confirm these findings. LEVEL OF EVIDENCE: 4.

Contribution of monoclonal antibodies to the study of parainfluenza virus antigens.

Splenic lymphocytes from BALB/c mice immunized with Parainfluenza 1 virus (PIV-1), HA2 strain, were fused to the non secreting 653 and secreting P3 X 63Ag8 myeloma cell lines. Fusion products were screened for antibody synthesis using an enzyme-linked immunosorbent assay (ELISA) with purified PIV-1. Antibodies were characterized by their biologic specificity and immune fluorescence staining--6 monoclones (2HI and 4 non HI) were used to further analysis by cross reactivity panels using different PIV strains. None of the anti PIV1 monoclones showed any cross reactivity with PIV2 and PIV3 whereas with HI and non HI monoclones antigenic relationships were observed between viruses belonging to serotype 1. Monoclonal antibodies were also applied to the study of host cell related changes in PIV1 proteins.